eXIthera Pharmaceuticals Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $201K

eXIthera Pharmaceuticals General Information

Description

Developer of novel, potent, and selective small molecule inhibitors designed to prevent thrombosis with limited risk for bleeding side effects and without the need for a reversal agent. The company focuses on developing stroke prevention and anti-thrombosis drugs that have a pathophysiological role in the initiation of intravascular thrombi without causing undue bleeding, enabling physicians to treat the serious consequences of venous thromboembolism, deep vein thrombosis, stroke, and heart attack.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1900 West Park Drive
  • Suite 280
  • Westborough, MA 01581
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 1900 West Park Drive
  • Suite 280
  • Westborough, MA 01581
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

eXIthera Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 15-Sep-2025 $201K Completed Clinical Trials - Phase 1
5. Later Stage VC 01-Jul-2022 Completed Clinical Trials - Phase 1
4. Later Stage VC 01-Apr-2019 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series B) 24-Aug-2017 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 16-May-2016 $10M $14M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 01-Jan-2013 $4M $4M Completed Clinical Trials - Phase 1
To view eXIthera Pharmaceuticals’s complete valuation and funding history, request access »

eXIthera Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view eXIthera Pharmaceuticals’s complete cap table history, request access »

eXIthera Pharmaceuticals Patents

eXIthera Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023185852-A1 Pharmaceutical composition for injection comprising cyclic lactam compound and method for preparing same Inactive 30-Mar-2022
WO-2023185791-A1 Preparation method for 2-aminopyridine derivative Inactive 28-Mar-2022
AU-2021343468-A1 Therapeutic compounds, compositions, and methods of use thereof Inactive 17-Sep-2020
CA-3192119-A1 Therapeutic compounds, compositions, and methods of use thereof Pending 17-Sep-2020
EP-4213857-A1 Therapeutic compounds, compositions, and methods of use thereof Inactive 17-Sep-2020 A61K31/4427
To view eXIthera Pharmaceuticals’s complete patent history, request access »

eXIthera Pharmaceuticals Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Clal Biotechnology Industries Venture Capital Minority
Haisco Pharmaceutical Group Company Corporation Minority
Schooner Capital Growth/Expansion Minority
To view eXIthera Pharmaceuticals’s complete investors history, request access »

eXIthera Pharmaceuticals FAQs

  • When was eXIthera Pharmaceuticals founded?

    eXIthera Pharmaceuticals was founded in 2012.

  • Where is eXIthera Pharmaceuticals headquartered?

    eXIthera Pharmaceuticals is headquartered in Westborough, MA.

  • What industry is eXIthera Pharmaceuticals in?

    eXIthera Pharmaceuticals’s primary industry is Drug Discovery.

  • Is eXIthera Pharmaceuticals a private or public company?

    eXIthera Pharmaceuticals is a Private company.

  • What is the current valuation of eXIthera Pharmaceuticals?

    The current valuation of eXIthera Pharmaceuticals is .

  • What is eXIthera Pharmaceuticals’s current revenue?

    The current revenue for eXIthera Pharmaceuticals is .

  • How much funding has eXIthera Pharmaceuticals raised over time?

    eXIthera Pharmaceuticals has raised $28.2M.

  • Who are eXIthera Pharmaceuticals’s investors?

    Clal Biotechnology Industries, Haisco Pharmaceutical Group Company, and Schooner Capital have invested in eXIthera Pharmaceuticals.

  • When was eXIthera Pharmaceuticals acquired?

    eXIthera Pharmaceuticals was acquired on 15-Sep-2025.

  • Who acquired eXIthera Pharmaceuticals?

    eXIthera Pharmaceuticals was acquired by Cadrenal Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process